Table 1

Laboratory and clinical parameters of ERA patients and healthy controls (HC)

ERAHC
0 months
(baseline)
3 months
(after treatment)
Patients, n606060
Females/males, n40/2040/2040/20
Age, years52.39 (2.06)52.43 (1.66)
DAS28 ESR5.33 (0.19)2.89 (0.20)
CRP, mg/L17.58 (2.90)5.91 (0.20)1.78 (0.22)
Anti-CCP positivity, n (%)30 (50%)
RF positivity, n (%)38 (63%)
csDMARDs/GCs, n (%)54/51 (90/85%)
Methotrexate, n (%)44 (73%)
Sulfasalazine, n (%)9 (17%)
Leflunomide, n (%)1 (1.5%)
  • Data are expressed as mean (SEM).

  • anti-CCP, anti-cyclic citrullinated peptide antibody; CRP, C reactive protein; csDMARDs, conventional synthetic disease-modifying antirheumatic drugs; DAS28 ESR, disease activity score in 28 joints with erythrocyte sedimentation rate; ERA, early stages of rheumatoid arthritis; RF, rheumatoid factor.